ASCEND BY NTHRYS
Research Abroad Products

Cancer Systems Biology Project Topics

Browse all focused areas across all project categories under this field.

Showing 169–180 of 200 project topics
Tumor Heterogeneity Mapping Engine for Clinical Decision Support
A SaaS tool that quantifies spatial and temporal tumor subclone diversity to predict treatment efficacy and metastatic potential at diagnosis. Healthcare systems implement this to stratify patients into risk cohorts, driving precision oncology adoption and premium care pricing.
Cancer Systems Biology Regulatory Evidence Tools Click to view more details →
Cancer Systems Biology Knowledge Graph and Query Engine
A commercial AI-powered platform that curates and connects millions of cancer biology interactions, enabling researchers to discover novel therapeutic hypotheses in minutes. Pharma companies subscribe to dramatically reduce target validation cycles and unlock early-stage pipeline opportunities.
Cancer Systems Biology Regulatory Evidence Tools Click to view more details →
Oncogenic Network Mapping SaaS Platform for Drug Discovery
A cloud-based platform that visualizes and analyzes tumor-specific signaling networks to identify novel drug targets and biomarker combinations. Enables pharmaceutical companies to accelerate target validation and reduce preclinical development costs by 40-60%.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Cancer Metabolism Profiling Tools and Biomarker Licensing
Proprietary software suite that quantifies metabolic reprogramming in patient tumors using multi-omics data integration and machine learning algorithms. Generates recurring licensing revenue through diagnostic partnerships and enables personalized metabolic inhibitor selection for oncology companies.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Tumor Microenvironment Computational Modeling and Simulation Engine
Enterprise software tool that simulates immune-cancer-stromal cell interactions to predict immunotherapy response and combination efficacy in silico. Monetizes through subscription licensing to biopharma firms, reducing failed clinical trials and accelerating time-to-market for immuno-oncology products.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Clonal Evolution Tracking Platform for Precision Oncology Services
Integrated analytics platform that monitors subclonal dynamics and predicts acquired resistance mechanisms using longitudinal sequencing data and systems biology models. Delivers recurring SaaS revenue through clinical laboratories and generates high-value consulting services for personalized treatment planning.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Synthetic Lethal Interaction Discovery Platform and IP Portfolio
High-throughput computational tool that identifies synthetic lethal gene pairs and drug combinations specific to tumor genotypes through network analysis and predictive modeling. Creates licensable intellectual property for combination therapy development and generates platform licensing fees from pharmaceutical partners.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Cancer Proteomics Data Integration SaaS for Target Selection
Cloud platform integrating mass spectrometry, phosphoproteomics, and network biology to map kinase dependencies and phosphorylation-driven oncogenic pathways. Enables pharma companies to validate undrugged targets and design targeted therapies, generating subscription revenue and data licensing partnerships.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Tumor-Host Systems Integration Platform for Biomarker Development
Proprietary software that models patient-specific tumor-immune-microbiome interactions to predict treatment response and toxicity risk across cancer cohorts. Monetizes through clinical implementation partnerships, companion diagnostic licensing, and premium consulting for precision medicine programs.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Network Pharmacology Engine for Polypharmacology Cancer Drug Design
Advanced computational platform that maps multi-target drug effects on cancer signaling networks to optimize efficacy while minimizing off-target toxicity. Licenses to pharma R&D departments for rational drug design and combination screening, generating usage-based SaaS revenue.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Patient-Derived Tumor Model Systems Integration and Analytics Service
Integrated service platform combining PDX/organoid generation with systems biology analysis to predict individual patient drug responses before clinical treatment. Creates recurring revenue through diagnostic testing, model licensing to pharma companies, and personalized medicine consulting services.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →
Cancer Cell State Plasticity Licensing Technology and Prediction Tools
Proprietary technology and software tools for predicting cancer cell phenotypic switching and therapy-induced state transitions using single-cell systems biology. Generates licensing revenue from biopharma companies designing therapies targeting cell state vulnerabilities and phenotypic transitions.
Cancer Systems Biology IP & Licensing Strategy Click to view more details →